BioVie Reports Phase 2 Long COVID Subgroup Improvements

BioVie said ADDRESS-LC data showed statistically significant improvements versus placebo in pre-specified subgroups with higher baseline fatigue, post-exertional malaise or cognitive impairment. The overall intent-to-treat population did not reach significance.